Categories: News

Arbutus to Participate in Upcoming Investor Conferences

WARMINSTER, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following upcoming virtual investor conferences:

H.C. Wainwright 23rd Annual Global Investment Conference (September 13-15, 2021)

  • Fireside Chat: available starting at 7:00 am ET on Monday, September 13, 2021
  • Presenters: William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
  • Webcast Link

Cantor Global Healthcare Conference (September 27-30, 2021)

  • Formal Presentation: Thursday, September 30, 2021 at 8:40 am ET
  • Presenter: William Collier, President and Chief Executive Officer
  • Webcast Link

The webcast links can also be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.

About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com

Pam Murphy
Investor Relations Consultant
Phone: 267-469-0914
Email: ir@arbutusbio.com

Staff

Recent Posts

Medexus Schedules Third Fiscal Quarter 2026 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP)…

49 minutes ago

In HelloNation, Family Counseling Expert Scott Ostrowski of Geneva Outlines Employee and Employer Support Services for HelloNation

GENEVA, N.Y., Feb. 3, 2026 /PRNewswire/ -- What are Employee and Employer Support Services, and…

49 minutes ago

In HelloNation, Dental Lab Specialist Jeffrey Tolksdorf of Clinton Township, MI, Details What Happens Inside a Dental Lab

CLINTON TOWNSHIP, Mich., Feb. 3, 2026 /PRNewswire/ -- What actually happens after your dentist takes…

49 minutes ago

In HelloNation, Water Treatment Expert Jason McGee of Loretto Explains the Importance of Precision in Water Treatment Chemistry

LORETTO, Tenn., Feb. 3, 2026 /PRNewswire/ -- How does precision in chemical dosing affect the…

49 minutes ago

GLOBO Language Solutions Elevates Leadership with Executive Promotions

PHILADELPHIA, Feb. 3, 2026 /PRNewswire/ -- GLOBO Language Solutions, the leading B2B provider of interpreting and…

49 minutes ago

Specialty1 Partners Continues to Accelerate Growth Through Its Industry-Leading Joint Venture Model

HOUSTON, Feb. 3, 2026 /PRNewswire/ -- Specialty1 Partners (S1P), the nation's fastest growing specialty dental…

50 minutes ago